BioSpace News Archive

Endeavor BioMedicines announced that data from a completed Phase 2a clinical trial evaluating the completed Phase 2a clinical trial evaluating the company’s lead investigational candidate ENV-101 in patients with idiopathic pulmonary fibrosis (IPF) will be presented for the first time in a late-breaking oral session at the American Thoracic Society 2024 (ATS 2024) International Conference. ATS 2024 will take place May 17-22, 2024, in San Diego.

ReCode Therapeutics today announced that company management will participate in the upcoming May conferences.

Kazia Therapeutics Limited is pleased to announce that the Safety Review Team (SRT) of the EVT801 Phase 1 clinical trial has concluded that the primary and secondary objectives of stage 1 of the trial have successfully been met.

Agilent Technologies Inc. announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately.

Astellas Pharma Inc. and Poseida Therapeutics, Inc. today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, “Xyphos”) and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.

The Melanoma Research Alliance, the world’s leading non-profit funder of melanoma research, announced its $12.6 million commitment to fund melanoma research supporting more than 30 scientists at leading academic and medical institutions in the United States and across the globe.

Bio-Rad Laboratories, Inc. today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).

Syra Health Corp. (NASDAQ: SYRA), (“Syra Health” or the “Company”) announced today that it will report financial results for its first quarter 2024 ended March 31, 2024, on Thursday, May 9, 2024, before the market opens.

NMDP BioTherapies announced today that CIBMTR CRO Services now offers a rapid clinical site selection and activation service, resulting in faster trial enrollment for cell and gene therapy (CGT) trials.

Exxel Pharma announced that Soren Mogelsvang, PhD, President and Chief Executive Officer of Exxel will present at the Virtual Investor Lunch Break: The Exxel Opportunity event on Wednesday, May 8, 2024 at 12:00 PM ET.